Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
Electrolytes & Blood Pressure
;
: 23-26, 2018.
Article
in English
| WPRIM
| ID: wpr-739604
ABSTRACT
A 22-year-old male patient was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). He received conservative treatment with an angiotensin-converting enzyme inhibitor. Two years later, oral therapy, consisting of 60 mg tolvaptan per day, was initiated. Compared with height-adjusted total kidney volume, the rate of kidney growth reduced significantly from 7.33% to 0.66% annually, since commencement of the tolvaptan therapy. The liver enzyme profile and serum sodium level and osmolality were constantly within normal ranges. In Korea, this is the first reported case of a patient with ADPKD who received tolvaptan treatment for more than 1 year. This case demonstrates that long-term tolvaptan treatment appears to be safe, well tolerated, and effective for ADPKD.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Osmolar Concentration
/
Reference Values
/
Sodium
/
Polycystic Kidney, Autosomal Dominant
/
Kidney
/
Korea
/
Liver
Limits:
Humans
/
Male
Country/Region as subject:
Asia
Language:
English
Journal:
Electrolytes & Blood Pressure
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS